Exemestane is a third-generation aromatase inhibitor originally developed by Pharmacia & Upjoin (now a subsidiary of Pfizer). It was first approved in the UK in April 1999 and has been marketed in several countries for clinical use in the treatment of advanced breast cancer in postmenopausal women. Exemestane tablets are an effective and selective treatment for postmenopausal hormone-dependent breast cancer. Exemestane tablets, as third-generation aromatase inhibitors, are with strong selectivity and long-lasting effects. They can also control breast cancer growth by inhibiting aromatase and blocking estrogen production.

According to CRI’s market research, Pharmacia & Upjoin’s exemestane was not introduced into the Chinese market until 2008, when several generic drugs from local Chinese companies were already available in the Chinese market, of which the exemestane tablets from Qilu Pharmaceutical was already marketed in China in 2002. Pharmacia &Upjoin’s exemestane (trade name AROMASIN^®) is extremely competitive in the Chinese market, accounting for more than 90% of China’s exemestane market in 2020 in terms of sales value. Despite the impact of the COVID-19 outbreak on the Chinese healthcare industry in early 2020, the sales value of exemestane in the Chinese market continued to grow in 2020, reaching approximately CNY400 million (USD61.6 million), with a CAGR of 9.2% from 2016 to 2020.

Breast cancer has replaced lung cancer as the number one cancer worldwide due to the rapid growth in the number of new cases in 2020. The increasing breast cancer cases are fundamentally caused by the altering risk factors for breast cancer, such as changing lifestyles and notions of marriage and childbearing due to economic growth, namely a general rise in the age of women having children, a decrease in the average number of births, overweight, obesity and lack of exercise, all contributing to the increase in the incidence of breast cancer. CRI expects that from 2021 to 2025, new cases of breast cancer in China will continue to grow, resulting in increases in both sales volume and value of exemestane in the Chinese market.

Topics Covered:

• Impact of COVID-19 on China’s Exemestane Market
• Development Environment of Exemestane in China
• Sales Volume of Exemestane in China
• Sales Volume and Value of Exemestane in China by Region
• Major Exemestane Manufacturers in China and Their Market Shares
• Sales Price of Exemestane in China
• Prospects of China’s Exemestane Market, 2021-2025

The post Research Report on China’s Exemestane Market, 2021-2025 first appeared on CRI Report.

Lung cancer is the most common type of cancer and the leading cause of cancer deaths. 19.29 million new cancer cases were diagnosed worldwide in 2020, 4.57 million of which were in China, accounting for 23.7%. There were 3 million cancer deaths in China in 2020, of which lung cancer deaths were up to 710,000, accounting for 23.8%.

Lung cancer is divided into small cell lung cancer and non-small cell lung cancer (NSCLC). Of all the lung cancer cases, NSCLC ones account for about 80-85% with most of them being diagnosed as advanced lung cancer (locally advanced or metastatic disease).

First-generation EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor), represented by gefitinib, can significantly prolong the median survival period of patients with advanced lung cancer carrying EGFR-sensitive mutations and improve the quality of life of patients.

Gefitinib, originally developed by AstraZeneca, is the world’s first marketed EGFR-TKI for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with sensitive mutations in the EGFR gene, as well as patients with locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy.

AstraZeneca’s gefitinib, with the trade name of Iressa^®, was approved in the United States in 2003 and in China in 2004.

Gefitinib was recommended by the Non-Small Cell Lung Cancer, Version 1.2020, NCCN Clinical Practice Guidelines and the Guidelines of Chinese Society of Clinical Oncology (CSCO) on Treatment of Primary Lung Cancer (2019) as a first-line drug for treatment for patients with EGFR-mutated non-small cell lung cancer, and has been included in the Category B in China’s medical insurance in 2019 and the National Essential Medicines List (2018 edition).

Before the launch of domestic generic drugs in China, the only gefitinib available in the market was the original drug Iressa with a high price. In 2017, the first generic drug from Qilu Pharmaceutical was approved for marketing in China to compete with Iressa, followed by generic drugs from Chia Tai Tianqing Pharmaceutical and Sichuan Kelun Pharmaceutical, Jiangsu Hengrui Medicine and Yangtze River Pharmaceutical.

In September 2019, in the Chinese government’s centralized drug-procurement, the gefitinib drugs of Qilu Pharmaceutical, Chia Tai Tianqing Pharmaceutical and AstraZeneca were selected at prices of CNY257, CNY450 and CNY547, with the specification of 25 mg (a box of 10 tablets). The price of AstraZeneca’s Iressa was reduced by 76%.

According to CRI’s market research, before 2019, the sales value of China’s gefitinib market kept growing year by year. In 2019, the average price of gefitinib decreased significantly due to the Chinese government’s centralized drug-procurement program. Therefore, although the sales volume of gefitinib in China increased in 2019, its sales value declined greatly.

In 2020, both of them decreased due to the COVID-19 outbreak, which impacted the proper function of Chinese healthcare institutions. The sales value of gefitinib in China was approximately CNY312 million (USD48.1 million) in 2020, with a CAGR of about 1.3% from 2016 to 2020.

According to CRI’s market research, although AstraZeneca’s original drug, Iressa, is much more expensive than generic drugs from local Chinese companies, it still held more than 70% share of the market in 2020 in terms of sales value.

CRI expects that from 2021 to 2025, China’s gefitinib market will show a recovery growth in both sales volume and value due to the effective control of COVID-19 and the resumption of proper operation of healthcare facilities.

CRI expects that, from 2021 to 2025, new cases of lung cancer in China will continue to grow as a result of environmental pollution and poor lifestyles. And with the growing income of Chinese residents, they are able to pay more for medical expenses. Therefore, China’s alectinib market is expected to grow in both sales volume and value during this period.

Topics Covered:

• Impact of COVID-19 on China’s Gefitinib Market
• Development Environment of Gefitinib in China
• Sales Volume of Gefitinib in China
• Sales Volume and Value of Gefitinib in China by Region
• Major Gefitinib Manufacturers in China and Their Market Shares
• Sales Price of Gefitinib in China
• Major Gefitinib Producers in China
• Prospects of China’s Gefitinib Market, 2021-2025

Related Reports: Global Bladder Cancer Detection Kit Market Analysis and Forecast Report 2030
Related Reports: Global Neoantigen Cancer Vaccine Market: Focus on Approach, Line of Therapy, Type, Application, Treatment Strategy, and Country-Wise Analysis – Analysis and Forecast, 2024-2031
Related Reports: Global Lung Cancer Surgery Market Analysis and Forecast Report 2030

The post Research Report on China’s Gefitinib Market, 2021-2025 first appeared on CRI Report.

The anti-cancer mechanism of platinum antitumor drugs can be divided into 4 steps: transmembrane transport, hydration dissociation, targeted migration, and acting on DNA to cause DNA replication disorder, thus inhibiting the division of cancer cells.

According to CRI’s market research, there are five types of platinum-based antitumor drugs commonly used in China: first-generation cisplatin, second-generation carboplatin and nedaplatin, third-generation oxaliplatin and lobaplatin. Lobaplatin, 1,2-diammino-methy lcyclobutane-platinum (II) lactate, was developed in Germany. In 2002, China’s Hainan Changan International Pharmaceutical purchased the patent right and the production and selling rights in China from ASAT, a German company. In 2005, its lobaplatin production was approved by the NMPA of China and marketed as a new Category I drug. In addition to affecting DNA synthesis and replication, its mechanism also affects the expression of the original tumor gene c-mye which is involved in oncogenesis, apoptosis and cell proliferation. The approved indications for lobaplatin in China are advanced breast cancer, small cell lung cancer and chronic myelomonocytic leukemia (CMML).

According to CRI’s market research, since its launch in China, lobaplatin showed an upward trend in sales volume and value from 2005 to 2019. In 2020, the sales value of lobaplatin in China declined to USD472 million due to the outbreak of COVID-19 at the beginning of the year which affected the proper functioning of Chinese healthcare institutions, but the CAGR from 2016 to 2020 was still up to 20.3%.

CRI expects that sales of lobaplatin in China will recover gradually from 2021 to 2025 as the COVID-19 is effectively controlled in the country. And the rising incidence of advanced breast cancer, small cell lung cancer and chronic granulocytic leukemia in China caused by increasing environmental pollution and changing lifestyles will boost the sales of lobaplatin. Generic drugs of lobaplatin are also expected to be available in China in the next few years, which will lower the average sales price of lobaplatin and increase the sales volume.

Topics Covered:

• The Impact of COVID-19 on China’s Lobaplatin Market
• The Incidence of Cancer in China
• The Development Environment of Lobaplatin in China
• Sales Volume of Lobaplatin in China
• Sales Volume and Value of Lobaplatin in China by Region
• Major Lobaplatin Manufacturers in China and Their Market Shares
• Price of Lobaplatin in China’s market
• Prospects of China’s Lobaplatin Market, 2021-2025

The post Research Report on China’s Lobaplatin Market, 2021-2025 first appeared on CRI Report.

Unlike other tumors, breast cancer can also be treated by endocrine therapy beside conventional treatments such as surgery, radiotherapy and chemotherapy. Endocrine therapy is applied to the whole treatment process of breast cancer patients from early adjuvant treatment to postoperative adjuvant treatment and recurrence salvage in clinical practice because it boasts good curative effect and can greatly reduce the risk of cancer coming back. Endocrine therapy for breast cancer is mainly achieved by oral medications.

Drugs for breast cancer endocrine therapy are divided into three categories, estrogen receptor modulators, aromatase inhibitors and estrogen receptor down-regulators. Anastrozole belongs to the second category and is indicated for the treatment of advanced breast cancer in postmenopausal women. Patients who are estrogen receptor negative but tamoxifen positive can take it. Anastrozole is also indicated for the adjuvant treatment of estrogen receptor-positive early-stage breast cancer in postmenopausal women.

Anastrozole was developed by AstraZeneca with Arimidex as its trade name. And it was first marketed in the United States in 1995, approved by the FDA of U.S. for the treatment of advanced breast cancer in postmenopausal women. 1999 saw the introduction of AstraZeneca’s anastrozole into China, where it was approved for use in the adjuvant treatment of estrogen receptor-positive early-stage breast cancer in postmenopausal women. In the following years, generic versions of anastrozole were launched by local Chinese companies. According to CRI’s market research, AstraZeneca still occupied more than 80% of China’s anastrozole market share in 2020 in terms of market value, thus having a huge competitive advantage.

According to CRI’s survey data, the sales value of anastrozole in China kept increasing year by year from 2016 to 2020, not much impacted by COVID-19. In 2020, the sales value of anastrozole in China was about CNY452 million, with a CAGR of 12.1% from 2016 to 2020.

CRI expects that with the rising incidence of breast cancer in China, anastrozole still has significant room for growth in the Chinese market. In addition, compared with other drugs of the same category, anastrozole has been clinically used earlier and is reimbursable under the medical insurance with little cost, and it has relatively fewer side effects as well. Some studies suggest that anastrozole may reduce the risk of invasive estrogen receptor-positive breast cancer and ductal carcinoma in situ in a high-risk postmenopausal breast population. New indications for anastrozole are also expected to be approved in China soon. According to CRI’s estimation, from 2021 to 2025, the sales volume and value of anastrozole in China will continue to grow.

Topics Covered:

• The Impact of COVID-19 on China’s Anastrozole Market
• Development Environment of Anastrozole in China
• Sales Volume of Anastrozole in China
• Sales Volume and Value of Anastrozole in China by Region
• Major Anastrozole Manufacturers in China and Their Market Share
• Sales Price of Anastrozole in China
• Prospects of China’s Anastrozole Market, 2021-2025

The post Research Report on China’s Anastrozole Market, 2021-2025 first appeared on CRI Report.

In China, the incidence of primary liver cancer ranked fifth among that of malignant tumors in 2020, with 410,000 new cases, including 303,000 cases in men; the mortality rate of the cancer ranked second with 391,000 deaths in 2020, a mortality rate of 17.2/100,000 of the total population. From 2016 to 2020, global average annual incidence of primary liver cancer was 995,000 cases, with Asia 732,000 cases, accounting for 73.6%, and China 423,000 cases, accounting for 42.5%. The high incidence of liver cancer in China is highly correlated with the fact that China is a country with high prevalence of hepatitis B, environmental pollution, and some spirits-addicted residents.

Liver cancer is a common malignant tumor in China. Liver cancer starts insidiously but progresses rapidly, and by the time it is detected, it is often at an advanced stage, making the treatment of surgery ineffective. Moreover, radiotherapy is of little use in treating liver cancer. Therefore, targeted drug therapy becomes the standard treatment for patients with advanced liver cancer. Sorafenib is the world’s first multi-targeted, multi-kinase inhibitor for the treatment of liver cancer. It can directly suppress tumor growth by inhibiting RAF/MEK/ERK signaling pathway, and indirectly suppress tumor growth by blocking the formation of tumor neovascularization through inhibiting VEGFR and PDGFR. Therefore, it is the first-line drug used for the treatment of advanced primary liver cancer.

Sorafenib is a multi-kinase inhibitor originally developed by Bayer AG with the trade name of Nexavar^®. Sorafenib was approved for marketing by the FDA of U.S. in December 2005 and approved by China in August 2006. In 2017, Bayer’s sorafenib was included in the category B of China’s national medical insurance catalog after a negotiated price reduction of about 70%, and the price after inclusion in medical insurance is about CNY200 (approximately USD30.8) per tablet. From 2018 to 2021, Bayer AG continues to reduce the price of sorafenib in the Chinese market.

According to CRI’s market research, the sales value of China’s sorafenib market continued to grow from 2016 to 2019. In 2020, the sales value declined to approximately USD406 million due to COVID-19, but the CAGR from 2016 to 2020 was still up to 22.3%.

As of August 2021, besides Bayer’s sorafenib product, only generic versions of Jiangxi Shanxiang Pharmaceutical and Chongqing Yaoyou Pharmaceutical have been officially marketed in the Chinese market. Some other companies such as Yabao Pharmaceutical Group and CSPC Ouyi Pharmaceutical have filed applications for the marketing of generic sorafenib drugs. In September 2020, The China National Intellectual Property Administration issued an invalidation request review decision (No. 46292), declaring that Bayer’s patent CN200680007187.1 for sorafenib mesylate in China was invalid. The invalidation petitioner was Chongqing Yaoyou Pharmaceutical. With the invalidation of Bayer’s patent applications related to sorafenib, more generic sorafenib drugs from local Chinese pharmaceutical companies will be launched in China.

For Bayer, as more generic drugs are approved and marketed, the market share of Nexavar in China will gradually decline. Bayer is expected to stop the decline of Nexavar’s market share through measures such as price cuts.

CRI expects that from 2021 to 2025, the average sales price of sorafenib in China will decline due to fierce competition while both sales volume and value will continue to rise.

Topics Covered:

• Impact of COVID-19 on China’s Sorafenib Market
• Development Environment of Sorafenib in China
• Sales Volume of Sorafenib in China
• Sales Volume and Value of Sorafenib in China by Region
• Major Sorafenib Manufacturers in China and Their Market Shares
• Sales Price of Sorafenib in China
• Prospects of China’s Sorafenib Market, 2021-2025

Related reports:

Investigation Report on Chinese Sorafenib Market, 2018-2022

The post Research Report on China’s Sorafenib Market, 2021-2025 first appeared on CRI Report.

About 85% of lung cancer patients suffer from NSCLC (non-small cell lung cancer), of which about 5% are ALK positive. ALK+NSCLC is caused by a gene fusion or rearrangement that over-activates the ALK protein, which is conducive to cancer cell growth and survival. ALK+NSCLC is a distinct cancer type commonly found in relatively younger lung cancer groups (at a median age of 52 years old) with no history of smoking. 50% in the groups are younger than 50 years old and approximately 70% in the groups have never smoked.

ALK inhibitors can suppress tumor growth by effectively disabling ALK activity. Among the ALK inhibitors that have been marketed, alectinib is one of the superior drugs.

Alectinib, originally developed by Roche, was first approved by the FDA on December 11, 2015, for patients with crizotinib-resistant ALK-positive non-small cell lung cancer. on November 6, 2017, the FDA also approved alectinib as a first-line agent for ALK-positive patients. Phase III clinical trials comparing alectinib and crizotinib for the first-line treatment of ALK-positive lung cancer patients showed that alectinib could significantly reduce the risk of disease progression or death by up to 57%, prolong patient disease-free survival by up to 34.8 months and delay brain metastases.

Because of the favorable efficacy of alectinib, authoritative guidelines at home and abroad like NCCN Guidelines 2019, CSCO Guidelines 2019 and ESMO Guidelines 2019 have unanimously recommended alectinib as a first-line priority for patients with ALK+ NSCLC.

According to CRI’s market research, Roche’s alectinib (trade name: Alecensa^®, manufactured by Excella GmbH & Co. KG) was approved for marketing in China in August 2018 for the indication of monotherapy of ALK-positive patients with locally advanced or metastatic NSCLC.

In the China National Reimbursement Drug List Negotiation 2019, Alectinib (only Alecensa is available in China as of August 2021) was included in the Category B of the National Drug Catalogue for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance, which came into effect on 1 January, 2020. In the Chinese market, a one-month dose of alectinib (150mg *224 capsules) cost CNY49,980 (USD7,690) before 2020. Then from 1 January, 2020, the price has reduced by more than 60%. However, for most Chinese patients, the monthly expenditure of approximately CNY15,230 (USD2,340) on alectinib is still too high. Since the annual disposable income per capita in China was only CNY32,189 (USD4,952) in 2020, which means the monthly disposable income per capita was less than USD500, there are still many Chinese patients cannot afford to purchase alectinib.

According to CRI’s market research, the sales value of alectinib in the Chinese market reached approximately CNY307 million (USD47.18 million) in 2020, with a CAGR of 815% from 2018 to 2020. The COVID-19 outbreak in early 2020 posed certain impact on the Chinese healthcare industry, but had minimal impact on its alectinib market.

CRI expects that, from 2021 to 2025, new cases of lung cancer in China will continue to grow as a result of environmental pollution and poor lifestyles. And with the growing income of Chinese residents, there are able to pay more for medical expenses. Therefore, China’s alectinib market is expected to grow in both sales volume and value during this period. Local Chinese pharmaceutical companies may also accelerate the production of generic alectinib drugs, but due to the great difficulty in production, it is expected that generic alectinib drugs from local Chinese pharmaceutical companies will not be available until around 2025 at the earliest.

Topics Covered:

• Impact of COVID-19 on China’s Alectinib Market
• Development Environment of Alectinib in China
• Sales Volume of Alectinib in China
• Sales Volume and Value of Alectinib in China by Region
• Major Alectinib Manufacturers in China and Their Market Shares
• Sales Price of Alectinib in China
• Prospects of China’s Alectinib Market, 2021-2025

Related reports:

Research Report on China’s Gefitinib Market, 2021-2025

The post Research Report on China’s Alectinib Market, 2021-2025 first appeared on CRI Report.

According to CRI’s market research, the sales of Capecitabine in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the COVID-19 pandemic on the hospital’s overall diagnosis and treatment services, sales in 2020 decreased to CNY 914 million, a year-on-year decrease of 9.31%. The CAGR of Capecitabine sales in the Chinese market from 2016 to 2020 is 1.21%.

CRI expects that with the easing of the COVID-19 pandemic, the sales of Capecitabine in the Chinese market will have a restorative growth in 2021-2025. In 2020, the number of COVID-19 breast cancers worldwide reached 2.26 million, and the number of colon cancers reached 1.93 million, both of which were on the rise. The number of breast and colon cancers in China will be also on the rise in the future. Therefore, the sales volume of Capecitabine, which is used to inhibit the anti-tumor activity of a variety of solid tumors, will increase with the increase in the number of breast cancer and colon cancer patients in China. There is also room for sales to rise. In addition, by the end of 2020, a number of companies led by Chengdu Yuandong Biopharmaceuticals have already reported for Capecitabine generic drug approval. In the next few years, more manufacturers will join the Chinese market. The sales volume and sales of Capecitabine in China are expected to rise.

Topics Covered:

• -The impact of COVID-19 on China’s Capecitabine market
• – Sales value of China’s Capecitabine 2016-2020
• – Competitive landscape of China’s Capecitabine market
• – Prices of Capecitabine in China
• – Prices of Capecitabine in China by regions and manufacturers
• – Analysis on factors affecting the development of China’s Capecitabine market
• – Prospect of China’s Capecitabine market from 2021 to 2025

The post Investigation Report on China’s Capecitabine Market 2021-2025 first appeared on CRI Report.